key: cord-0711272-8bvvabsf
authors: Jang, Tyng‐Yuan
title: Suppression of hepatitis C virus replication during COVID‐19 infection
date: 2022-01-20
journal: Kaohsiung J Med Sci
DOI: 10.1002/kjm2.12498
sha: fbd9245f1a87d3cc5d3ce78a0caa782927b8ce74
doc_id: 711272
cord_uid: 8bvvabsf

nan

at the Taiwan CDC laboratory or in a designated laboratory at hospitals. She was isolated in a negative pressure ward at a government hospital in Pingtung, Taiwan. The initial biochemical analysis results were abnormal for aspartate aminotransferase (AST) (47 IU/L), and the hepatitis C antibody (Anti-HCV) was positive. This was the first time she was diagnosed with HCV infection. The concurrent HCV RNA titer was low (140 IU/mL) ( Table 1) . Remdesivir was administered for COVID-19 infection and she was discharged after 2 weeks 

Importation of SARS-CoV-2 infection leads to major COVID-19 epidemic in Taiwan

Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing

Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection

Clinical and laboratory characteristics of hepatitis C and COVID-19 coinfection: prolonged RNA shedding in nonhospitalized case

Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study

Email: sls0902000@gmail.com ORCID Tyng-Yuan Jang https://orcid.org/0000-0003-2961-130X